NCT00753935View on ClinicalTrials.gov

Aspirin Resistance in Coronary Artery Disease

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 31, 2011

Study Completion Date

March 31, 2014

Conditions
Coronary Artery Disease
Interventions
DRUG

enteric-coated aspirin

enteric-coated aspirin 81mg daily for 2 weeks

DRUG

Chewable aspirin

chewable aspirin 81mg daily for 2 weeks

Trial Locations (1)

37232

Vanderbilt University, Nashville

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University

OTHER

NCT00753935 - Aspirin Resistance in Coronary Artery Disease | Biotech Hunter | Biotech Hunter